Baird Downgrades Edwards Lifesciences to Neutral, Lowers Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Baird analyst David Rescott has downgraded Edwards Lifesciences (NYSE:EW) from Outperform to Neutral and lowered the price target from $102 to $70.
July 25, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird analyst David Rescott downgraded Edwards Lifesciences from Outperform to Neutral and reduced the price target from $102 to $70.
The downgrade from Outperform to Neutral and the significant reduction in the price target from $102 to $70 by a reputable analyst is likely to negatively impact investor sentiment and the stock price of Edwards Lifesciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100